Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostatecancer. Multiparametric magnetic resonance imaging (MRI), with or without MRI-targeted biopsy, is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostatecancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision-making.To determine the diagnostic accuracy of the index tests MRI only, MRI (...) -targeted biopsy, the MRI pathway (MRI with or without MRI-targeted biopsy) and systematic biopsy as compared to template-guided biopsy as the reference standard in detecting clinically significant prostatecancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher-grade prostatecancer, and a potential change in the number of biopsy procedures.We performed
Abiraterone acetate (prostatecancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Abirateronacetat (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-64 (...) Abiraterone acetate (prostatecancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-64 Version 1.0 Abiraterone acetate (prostatecancer) 13 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Abiraterone acetate (prostatecancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission
ProstateCancerProstateCancer | Uroweb › ProstateCancerProstateCancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . N. Mottet (Chair), R.C.N. van den Bergh, E. Briers (Patient Representative), P. Cornford (Vice-chair), M. De Santis, S. Fanti, S. Gillessen, J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel, O. Rouvière, D. Tilki, T. Wiegel (...) Guidelines Associates: T. Van den Broeck, M. Cumberbatch, N. Fossati, T. Gross, M. Lardas, M. Liew, L. Moris, I.G. Schoots, P-P.M. Willemse TABLE OF CONTENTS REFERENCES 1. Drost, F.J.H., et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostatecancer. Cochrane Database of Systematic Reviews, 2019. In press. 2. Van den Broeck, T., et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for ProstateCancer: A Systematic Review
Abiraterone acetate (prostatecancer) - Addendum to Commission A17-64 1 Translation of addendum A18-26 Abirateronacetat (Prostatakarzinom) – Addendum zum Auftrag A17-64 (Version 1.0; Status: 11 May 2018). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 11 May 2018 1.0 Commission: A18-26 Version: Status: IQWiG Reports – Commission No. A18-26 Abiraterone (...) acetate (prostatecancer) – Addendum to Commission A17-64 1 Addendum A18-26 Version 1.0 Abiraterone acetate – Addendum to Commission A17-64 11 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Abiraterone acetate (prostatecancer) – Addendum to Commission A17-64 Commissioning agency: Federal Joint Committee Commission awarded on: 25 April 2018 Internal Commission No.: A18-26 Address
Apalutamide (Erleada) - cancer of the prostate EMA/810516/2018 EMEA/H/C/004452 Erleada (apalutamide) An overview of Erleada and why it is authorised in the EU What is Erleada and what is it used for? Erleada is a cancer medicine used to treat men with cancer of the prostate (a gland of the male reproductive system). It is used when the cancer is not responding to treatments that lower testosterone levels and is at high risk of spreading to other parts of the body. Erleada contains the active (...) substance apalutamide. How is Erleada used? Erleada is available as tablets (60 mg) to be taken by mouth. The recommended dose is 4 tablets (240 mg) a day. Treatment may be stopped temporarily and later restarted at a reduced dose if the patient experiences intolerable side effects. Erleada can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of prostatecancer. For more information about using Erleada, see the package leaflet
Use of Low-Dose Aspirin and Mortality After ProstateCancer Diagnosis: A Nationwide Cohort Study. Recent studies suggest that aspirin use may improve survival in patients with prostate cancer.To assess the association between postdiagnosis use of low-dose aspirin and prostatecancer mortality.Nationwide cohort study.Denmark.Men with incident prostate adenocarcinoma between 2000 and 2011.Nationwide registry data on tumor characteristics, drug use, primary prostatecancer therapy, comorbidity (...) , and socioeconomic parameters. Postdiagnosis use of low-dose aspirin (75 to 150 mg) was defined as 2 or more prescriptions filled within 1 year after prostatecancer diagnosis. Follow-up started 1 year after prostatecancer diagnosis. In secondary analyses, low-dose aspirin use was assessed within exposure periods of 5 or 7.5 years after prostatecancer diagnosis.Of 29 136 patients (median age, 70 years), 7633 died of prostatecancer and 5575 died of other causes during a median follow-up of 4.9 years
Axumin for functional imaging of prostatecancer recurrence Axumin for functional imaging of prostatecancer Axumin for functional imaging of prostatecancer recurrence recurrence Medtech innovation briefing Published: 8 February 2019 nice.org.uk/guidance/mib172 pathways Summary Summary The technology technology described in this briefing is Axumin, a radiopharmaceutical agent. It is intended for use in positron emission tomography (PET) to detect suspected prostatecancer recurrence in people (...) who have elevated prostate-specific antigen levels after primary curative treatment. It is currently the only licensed PET tracer indicated for use in recurrent prostatecancer. The inno innovativ vative aspects e aspects are that it is a prostatecancer-specific PET tracer with a novel mechanism of action based on amino acid transport. Its longer half-life and shorter uptake period may allow use in more people with suspected prostatecancer recurrence compared with other PET tracers. The intended
Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostatecancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status (...) Incomplete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostatecancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostatecancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared
Remote monitoring or self-management for surveillance or follow up of prostatecancer Remote monitoring of prostatecancer - Health Technology Wales > Remote monitoring of prostatecancer Remote monitoring of prostatecancer Topic Status Incomplete Remote monitoring or self-management for surveillance or follow up of prostatecancer. Summary Health Technology Wales researchers searched for evidence on different methods of prostate remote monitoring/self-management. Although a range of evidence
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant ProstateCancer: Results from a Phase II Randomized Trial Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL).To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide.We randomized 202 patients in a phase II study of abiraterone versus (...) enzalutamide for first-line treatment of metastatic castration-resistant prostatecancer (ClinicalTrials.gov: NCT02125357).Patients completed Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Patient Health Questionnaire-9 (PHQ-9) questionnaires, and Montreal Cognitive Assessment (MoCA) cognitive assessments at baseline and on treatment.To compare the change in FACT-P scores over time between treatment arms, we used a mixed model for repeated measures (MMRM). For FACT-P domains where
Biodegradable Rectal Spacers for ProstateCancer Radiotherapy Recommendation Report 21-5 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Biodegradable Rectal Spacers for ProstateCancer Radiotherapy P Chung, J Brown, D D‘Souza, W Koll, S Morgan and the biodegradable spacer insertion during radiotherapy for prostatecancer recommendation report group (SPACER RRG) Report Date: January 16, 2019 For information about this document, please contact Dr (...) Spacers for ProstateCancer Radiotherapy. Toronto (ON): Cancer Care Ontario: 2019, January 16. Program in Evidence- based Care Recommendation Report No.: 21-5. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization. Disclaimer Care has been taken
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostatecancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, The optimal duration of androgen suppression for men with locally advanced prostatecancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic acid is effective in preventing androgen suppression-induced bone loss (...) , but its role in preventing castration-sensitive bone metastases in locally advanced prostatecancer is unclear. The RADAR trial assessed whether the addition of 12 months of adjuvant androgen suppression, 18 months of zoledronic acid, or both, can improve outcomes in men with locally advanced prostatecancer who receive 6 months of androgen suppression and prostatic radiotherapy. This report presents 10-year outcomes from this trial.For this randomised, phase 3, 2 × 2 factorial trial, eligible men
Men feel physically and psychologically ill-prepared for prostatecancer surgery Men feel physically and psychologically ill-prepared for prostatecancer surgery Discover Portal Discover Portal Men feel physically and psychologically ill-prepared for prostatecancer surgery Published on 28 November 2017 doi: Following prostatecancer surgery men often experience physical changes, such as urinary incontinence and erectile dysfunction, causing negative emotions and distress. This review found (...) that men felt poorly prepared – psychologically and physically – for the changes they might experience after surgery. Surgery was often described as "life-changing", and men described worrying about their future. NICE recommend that men and their partners/carers are fully informed about prostatecancer treatment options and their possible complications, and are supported in decision-making. This includes having access to psychosexual support at any time. This global review represents the views of men
MRI scan before biopsy could detect more prostatecancer MRI scan before biopsy could detect more prostatecancer Discover Portal Discover Portal MRI scan before biopsy could detect more prostatecancer Published on 7 March 2017 doi: In men with a raised prostate specific antigen (PSA) blood test, which can be a sign of prostatecancer, MRI scanning before standard biopsy could allow more targeted biopsies and increase diagnosis of medium and high-risk prostatecancer. In this NIHR-funded study (...) , 576 men with suspected prostatecancer received a multi-parametric (MP)-MRI scan in addition to transrectal ultrasound-guided (TRUS) biopsy. They also had template mapping (TPM) biopsy of the entire prostate to reliably diagnose cancer. Neither MP-MRI scan nor TRUS-biopsy were entirely accurate. However, if MP-MRI is used as an initial test, followed by TRUS-biopsy targeted at areas identified on the scan, 18% more cancers could be detected than by TRUS biopsy alone. It may also help avoid
Large ten-year trial on treatment of localised prostatecancer will aid management decisions Large ten-year trial on treatment of localised prostatecancer will aid management decisions Discover Portal Discover Portal Large ten-year trial on treatment of localised prostatecancer will aid management decisions Published on 15 September 2016 doi: New, long-term research indicates that active monitoring, with prompt treatment if needed, may be a better option than radical surgery or radiotherapy (...) for many men who have prostatecancer if it’s confined to the prostate gland. In the ProtecT trial, after an average of ten years, few men died of prostatecancer and there was no difference in survival between men receiving active monitoring and those who had radical treatments (which caused unpleasant side effects). But active monitoring did increase the risk of cancer progressing or spreading to other parts of the body. Longer follow-up will help to fully understand the balance between treatments
Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone Discover Portal Discover Portal Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone Published on 27 September 2016 doi: The drug zoledronic acid delayed the onset of bone complications by two months in men with prostatecancer (...) strontium-89 to treat prostatecancer that has spread to the bone, but not zoledronic acid unless other treatment has failed due to costs. The branded version of zoledronic acid did not give value for money but cheaper generic versions, now available, could be a better use of NHS resources. Share your views on the research. Why was this study needed? Prostatecancer is the second most common cause of cancer deaths in men in the UK. Just over 10,000 men died from prostatecancer in 2009. The rate has
Single routine offer of a blood test for prostatecancer did not save lives Single routine offer of a blood test for prostatecancer did not save lives Discover Portal Discover Portal Single routine offer of a blood test for prostatecancer did not save lives Published on 12 June 2018 doi: Offering all men aged 50 to 69 a single, screening prostate-specific antigen (PSA) blood test did not prevent deaths from prostatecancer. This large trial included 573 UK general practices and over 400,000 (...) men. It found that men who were invited to have a PSA test were 19% more likely to be diagnosed with prostatecancer, but no less likely to die from the condition, over an average 10 years of follow up. Forty per cent of men took up the offer. Controversy over PSA testing has persisted for many years. Two previous trials have had conflicting findings about whether repeated PSA testing reduces prostatecancer deaths. In addition, concerns about test accuracy, over-diagnosis and over-treatment have
Factors in men’s choice of active surveillance for low-risk prostatecancer Factors in men’s choice of active surveillance for low-risk prostatecancer Discover Portal Discover Portal Factors in men’s choice of active surveillance for low-risk prostatecancer Published on 7 August 2018 doi: Many personal, organisational and national factors can help or hinder men from choosing active surveillance over radical treatment when they have low-risk prostatecancer. Men are more likely to adhere (...) to this plan of regular monitoring if they and their families are fully informed and understand that it includes the option of further treatment if necessary. The recent ProtecT trial demonstrated that there was no difference in 10-year survival rates between men with low risk localised prostatecancer who were allocated to active surveillance and those who chose radical treatment. This is important because radical treatment carries the risk of side effects, such as incontinence and erectile dysfunction
Radiotherapy benefits some men whose prostatecancer has spread to their bones Radiotherapy benefits some men whose prostatecancer has spread to their bones Discover Portal Discover Portal Radiotherapy benefits some men whose prostatecancer has spread to their bones Published on 22 January 2019 doi: Adding radiotherapy directed at the prostate to hormone treatment for all men with metastatic prostatecancer makes no difference to overall survival. However, when men with a limited number (...) of metastases confined to the bones of the pelvis and spine are treated with radiotherapy to the prostate, their survival improves. The standard treatment for men with metastatic prostatecancer is anti-androgen hormone therapy, and this is sometimes combined with chemotherapy. Radiotherapy of the prostate itself is only usually used for symptom relief. This NIHR part-funded trial compared the effects of standard care with or without radiotherapy to the prostate on overall survival for over 2,000 men